For the treatment of Neuropsychiatric Symptoms in Parkinson’s Disease

Hippocampal hyperactivity is a pathological hallmark of Alzheimer’s disease (AD) and a prognostic indicator of AD progression and clinical cognitive worsening in amnestic mild cognitive impairment (aMCI). Clinical studies testing the efficacy of AGB101, a proprietary extended-release formulation of low dose levetiracetam, have shown benefit in prodromal AD normalizing hippocampal hyperactivity and significantly improving memory function in these participants. Here we present preliminary neuroimaging data suggesting the condition of hippocampal overactivity also contributes to cognitive impairment in other conditions including neuropsychiatric symptoms in patients with Parkinson’s disease (PD).